HK1067645A1 - Tumor antigen peptides originating in cyclophilin b - Google Patents

Tumor antigen peptides originating in cyclophilin b

Info

Publication number
HK1067645A1
HK1067645A1 HK04109605A HK04109605A HK1067645A1 HK 1067645 A1 HK1067645 A1 HK 1067645A1 HK 04109605 A HK04109605 A HK 04109605A HK 04109605 A HK04109605 A HK 04109605A HK 1067645 A1 HK1067645 A1 HK 1067645A1
Authority
HK
Hong Kong
Prior art keywords
tumor antigen
antigen peptides
cyclophilins
cyclophilin
derivatives
Prior art date
Application number
HK04109605A
Other languages
English (en)
Inventor
Kyogo Itoh
Shinya Gomi
Original Assignee
Kyogo Itoh
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyogo Itoh, Dainippon Sumitomo Pharma Co filed Critical Kyogo Itoh
Publication of HK1067645A1 publication Critical patent/HK1067645A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
HK04109605A 1998-06-25 2004-12-03 Tumor antigen peptides originating in cyclophilin b HK1067645A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17844998 1998-06-25
PCT/JP1999/003360 WO1999067288A1 (fr) 1998-06-25 1999-06-24 Peptides d'antigenes tumoraux provenant de la cyclophiline b

Publications (1)

Publication Number Publication Date
HK1067645A1 true HK1067645A1 (en) 2005-04-15

Family

ID=16048723

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109605A HK1067645A1 (en) 1998-06-25 2004-12-03 Tumor antigen peptides originating in cyclophilin b

Country Status (15)

Country Link
US (2) US7041297B1 (xx)
EP (1) EP1090924B8 (xx)
JP (1) JP4413429B2 (xx)
KR (1) KR100653590B1 (xx)
CN (1) CN1318447C (xx)
AT (1) ATE375362T1 (xx)
AU (1) AU749544B2 (xx)
CA (1) CA2331761A1 (xx)
DE (1) DE69937294T2 (xx)
ES (1) ES2294844T3 (xx)
HK (1) HK1067645A1 (xx)
ID (1) ID27788A (xx)
NZ (1) NZ508996A (xx)
TW (1) TWI228128B (xx)
WO (1) WO1999067288A1 (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105306B1 (en) * 2000-08-10 2006-09-12 Trustees Of The University Of Pennsylvania Methods and compositions for modulating somatolactogenic functions
DE60020981T2 (de) * 1999-09-10 2005-12-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. ANT-1 als Arzneimittelziel
WO2001052858A1 (en) * 2000-01-24 2001-07-26 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
AU2001259701A1 (en) * 2000-05-15 2001-11-26 Paratek Pharmaceuticals, Inc 7-substituted fused ring tetracycline compounds
AU2001268475A1 (en) * 2000-06-16 2002-01-02 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
AU2002365120A1 (en) 2001-08-02 2003-07-15 Paratek Pharmaceuticals, Inc. Medicaments
EP2267023B1 (en) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
CA2538300A1 (en) * 2003-09-22 2005-03-31 Green Peptide Co., Ltd. Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent
TWI261038B (en) * 2004-08-11 2006-09-01 Bo-Cheng Chen Bicycle gear-shifting handgrip
AU2005299294B2 (en) 2004-10-25 2012-06-07 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
JP4829961B2 (ja) 2006-05-01 2011-12-07 日立化成工業株式会社 プロスタシン部分ペプチド及び抗プロスタシン抗体
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
WO2008072777A2 (en) 2006-12-13 2008-06-19 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer
WO2008099908A1 (ja) 2007-02-16 2008-08-21 Oncotherapy Science, Inc. 脈絡膜新生血管のワクチン療法
TWI434853B (zh) 2007-04-11 2014-04-21 Oncotherapy Science Inc 腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
RU2010111135A (ru) 2007-08-24 2011-10-27 Онкотерапи Сайенс, Инк. (Jp) Связанные со злокачественными опухолями гены cdca5. epha7. stk31 и wdhd1
CA2927770C (en) 2007-09-18 2017-09-19 Green Peptide Co., Ltd. Ctl inducer composition
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1抗原決定位胜肽及含此胜肽的疫苗
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1胜肽以及含此胜肽之疫苗
WO2010106770A1 (en) 2009-03-18 2010-09-23 Oncotherapy Science, Inc. Neil3 peptides and vaccines including the same
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Cdc45l胜肽與含此胜肽之疫苗
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
RU2570560C2 (ru) 2010-03-11 2015-12-10 Онкотерапи Сайенс, Инк. Пептиды hjurp и содержащие их вакцины
US9725490B2 (en) 2011-07-29 2017-08-08 Tokushima University ERAP1-derived peptide and use thereof
RU2612905C2 (ru) 2011-08-12 2017-03-13 Онкотерапи Сайенс, Инк. Пептиды mphosph1 и вакцины, включающие их
CA2852633C (en) 2011-10-28 2021-08-03 Oncotherapy Science, Inc. Topk peptides and vaccines including the same
US9561265B2 (en) 2012-07-10 2017-02-07 Oncotherapy Science, Inc. KIF20A epitope peptides for TH1 cells and vaccines containing the same
WO2014010232A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Ly6k epitope peptides for th1 cells and vaccines containing the same
SG10201701866QA (en) 2012-09-11 2017-04-27 Oncotherapy Science Inc Ube2t peptides and vaccines containing the same
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Kntc2胜肽及含此胜肽之疫苗
PT3061771T (pt) 2013-10-21 2020-05-06 Taiho Pharmaceutical Co Ltd Novo péptido unido a quatro epitopos ctl
CN111925414A (zh) 2014-08-04 2020-11-13 肿瘤疗法科学股份有限公司 Koc1衍生的肽和包含它们的疫苗
US10676514B2 (en) 2014-08-04 2020-06-09 Oncotherapy Science, Inc. CDCA1-derived peptide and vaccine containing same
IL250235B (en) 2014-08-04 2022-07-01 Oncotherapy Science Inc A peptide derived from urlc10 and a component containing it
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
US20210236613A1 (en) 2018-06-29 2021-08-05 Taiho Pharmaceutical Co., Ltd. Antitumor agent and evaluation method thereof
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
WO2020111167A1 (ja) 2018-11-30 2020-06-04 国立大学法人徳島大学 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
KR20220120627A (ko) 2019-12-26 2022-08-30 다이호야쿠힌고교 가부시키가이샤 수술 후 보조 요법제
CN115078727A (zh) * 2022-07-13 2022-09-20 首都医科大学附属北京胸科医院 一种预测癌症免疫治疗效果的标志物、试剂盒与应用
DE102022118517A1 (de) 2022-07-25 2024-01-25 Dennis Reitmeir Liegestützvorrichtung mit drehbaren Griffeinheiten
CN115372618A (zh) * 2022-09-19 2022-11-22 首都医科大学附属北京胸科医院 一种检测蛋白标志物水平的试剂在制备用于评估肿瘤治疗效果的诊断产品中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326067A3 (en) * 1988-01-26 1991-04-17 The Du Pont Merck Pharmaceutical Company Use of cyclophilin as an anti-inflammatory and immunomodulatory agent
DE69334076D1 (de) 1992-08-07 2006-11-30 Pharmexa Inc Hla bindepeptide und ihre verwendungen
JPH09151200A (ja) * 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein

Also Published As

Publication number Publication date
WO1999067288A9 (fr) 2000-03-30
CN1525980A (zh) 2004-09-01
WO1999067288A1 (fr) 1999-12-29
EP1090924A4 (en) 2002-07-10
US7041297B1 (en) 2006-05-09
KR20010053180A (ko) 2001-06-25
US7368107B2 (en) 2008-05-06
ATE375362T1 (de) 2007-10-15
EP1090924B8 (en) 2007-11-21
EP1090924B1 (en) 2007-10-10
ID27788A (id) 2001-04-26
US20060008463A1 (en) 2006-01-12
EP1090924A1 (en) 2001-04-11
AU4392699A (en) 2000-01-10
CN1318447C (zh) 2007-05-30
ES2294844T3 (es) 2008-04-01
NZ508996A (en) 2003-09-26
JP4413429B2 (ja) 2010-02-10
DE69937294T2 (de) 2008-07-03
CA2331761A1 (en) 1999-12-29
KR100653590B1 (ko) 2006-12-04
DE69937294D1 (de) 2007-11-22
AU749544B2 (en) 2002-06-27
TWI228128B (en) 2005-02-21

Similar Documents

Publication Publication Date Title
EP1090924B8 (en) Tumor antigen peptides originating in cyclophilin b
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO1997014806A3 (en) Delivery of biologically active polypeptides
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
CA2216535A1 (en) Protein kinase c inhibitors
EP2295453A3 (en) An appetite-suppressing peptide, its compositions and use
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2000029574A3 (en) Inflammation-associated genes
EP1571216A3 (en) Phosphodiesterase 8A
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
EP1364657A4 (en) REMEDIES AGAINST TUMORS AFFECTING HEMATOPOIETIC BODIES
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
CA2246222A1 (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110624